INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service, Department of Virology, Sorbonne Université, Paris, France.
INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France.
Microbiol Spectr. 2022 Oct 26;10(5):e0192222. doi: 10.1128/spectrum.01922-22. Epub 2022 Sep 20.
Large-scale screening for SARS-CoV-2 infection is an important tool for epidemic prevention and control. The appearance of new variants associated with specific mutations can call into question the effectiveness of rapid diagnostic tests (RDTs) deployed massively at national and international levels. We compared the clinical and virological characteristics of individuals infected by Delta or Omicron variants to assess which factors were associated with a reduced performance of RDT. A commercially available RDT as well as the evaluation of the viral load (VL) and the detection of replicate intermediates (RIs) were carried out retrospectively on positive SARS-CoV-2 nasopharyngeal specimens from health care workers of the Pitié-Salpêtrière Hospital infected by the Delta or Omicron variant between July 2021 and January 2022. Of the 205 samples analyzed (104 from individuals infected with Delta and 101 with Omicron), 176 were analyzed by RDT and 200 by RT-PCR for VL and RIs. The sensitivity of the TDR for Omicron was significantly lower than that observed for Delta (53.8% 74.7%, respectively, < 0.01). Moreover, the Delta VL was significantly higher than that measured for Omicron (median Ct 21.2 24.1, respectively, < 0.01) and associated with the positivity of the RDT in multivariate analysis. We demonstrate a lower RDT sensitivity associated with a lower VL at the time of diagnosis on Omicron-infected individuals in comparison to those infected with the Delta variant. This RDT lower sensitivity should be taken into account in the large-scale screening strategy and in particular in case of strong suspicion of infection where testing should be repeated. Previous reports have shown a variability in the diagnostic performance of RDTs. In the era of SARS-CoV-2 variants and the use of RDT, mutation associated with these variants could affect the test performance. We evaluate the sensitivity of the RDT Panbio COVID-19 Ag (Abbott) with two variants of concern (VOC), the Delta and Omicron variants. In order to investigate whether clinical characteristics or virological characteristics can affect this sensitivity, we collected clinical information and performed a specific RT-PCR that detected the RIs as a marker of the viral replication and viral cycle stage. Our results showed that Omicron was less detected than the Delta variant. A lower viral load of Omicron variant in comparison to Delta variant explained this decreased sensitivity, even if they are at the same stage of the disease and the viral cycle and should be taken into account with the use of RDT as diagnostic tool.
大规模筛查 SARS-CoV-2 感染是疫情防控的重要手段。与特定突变相关的新变体的出现可能会质疑在国家和国际层面大规模部署的快速诊断检测(RDT)的有效性。我们比较了感染 Delta 或 Omicron 变体的个体的临床和病毒学特征,以评估哪些因素与 RDT 性能降低有关。对 2021 年 7 月至 2022 年 1 月期间在皮提-萨尔佩特里埃医院工作的医护人员感染的 Delta 或 Omicron 变体的鼻咽拭子阳性标本进行了商业上可用的 RDT 以及病毒载量(VL)和复制中间体(RI)检测的回顾性评估。在分析的 205 个样本中(104 个来自感染 Delta 的个体,101 个来自感染 Omicron 的个体),176 个用 RDT 分析,200 个用 RT-PCR 分析 VL 和 RI。对于 Omicron,TDR 的灵敏度明显低于 Delta(分别为 53.8%和 74.7%,<0.01)。此外,Delta 的 VL 明显高于 Omicron(中位数 Ct 分别为 21.2 和 24.1,<0.01),并且在多变量分析中与 RDT 阳性相关。与感染 Delta 变体的个体相比,我们在感染 Omicron 的个体中观察到与较低 VL 相关的 RDT 灵敏度降低。在大规模筛查策略中,特别是在强烈怀疑感染的情况下,应该考虑到这种 RDT 较低的灵敏度,并且应该重复检测。之前的报告显示 RDT 的诊断性能存在差异。在 SARS-CoV-2 变体时代和 RDT 的使用中,与这些变体相关的突变可能会影响测试性能。我们评估了 Panbio COVID-19 Ag(Abbott)RDT 对两种关注变体(VOC),Delta 和 Omicron 变体的灵敏度。为了研究临床特征或病毒学特征是否会影响这种敏感性,我们收集了临床信息并进行了特定的 RT-PCR 检测,该检测检测 RI 作为病毒复制和病毒周期阶段的标志物。我们的结果表明,与 Delta 变体相比,Omicron 的检测率较低。与 Delta 变体相比,Omicron 变体的病毒载量较低,这解释了这种敏感性降低,即使它们处于相同的疾病和病毒周期阶段,并且应该在使用 RDT 作为诊断工具时考虑到这一点。